Shake the hand of someone who… 🤝 Part ONE!
Connecting across disciplines, experiences, and a shared mission to move kidney cancer research forward.
#IKCSEU26#KidneyCancer#Oncology#CancerResearch
Still time to register!
Join us this Thursday in Center City for a phenomenal, practice-changing review of everything happening in GU Oncology - and yes, a great meal too!
It’s hard to believe Americas 🇺🇸 🇨🇦 3-0 down in the Uromigos Cup 🏆 . Weekly photos from each team from around the world wins points . ❤️ =points. Can the Americas 🇺🇸🇨🇦 catch up ? Here is @walterstadler5 in Chicago. @OncoAlert@montypal@crisuarez08@DrChoueiri
Phase 2 trial: In oligometastatic clear-cell RCC, serial metastasis-directed therapy (no systemic Tx) achieved median 34 mo systemic therapy-free survival & 17.7 mo PFS with low grade 3–4 toxicity. A promising option for select pts.
🔎To finish discussion need to 3 arms phase-3 trial:
👉MDT only vs. Systemic Tx only vs. MDT+Systemic Tx
@OncoAlert@TheLancet #cancer #Oncology #MedX
https://t.co/V7p5if1kBw
@uretericbud@cancerdrlane Influenced so many patients and colleagues - much more than he ever knew. Heaven will welcome him but we will miss this true giant in the field. Rest peacefully
Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 https://t.co/AMqlUvlkNG and https://t.co/W8gO8lWxQo @PCFnews@urotoday@OncoAlert
📣 Live at #ASCO25: Learn from real-world #RCC cases with @montypal, Dr. McDermott & @TiansterZhang
✅ IO-based regimens
✅ Sequencing therapies
✅ Shared decision-making
🗓️ May 31 | 7:00 PM CDT
🔗 https://t.co/PNSrNPyw2J